In episode six of Pharma Decrypted, Sabine Louët is in conversation with Nicolas Rosen, founder of Exaris, about a question which came up whilst building ScioWire, SciencePOD’s news feed for digital-native HCPs
Interview with Vicky Ngo, AVP, International Lead, Digital Human Health, MSD
In episode five of Pharma Decrypted, Sabine Louët was joined by Emmet Kearney, CEO at Altuent, a company working in the knowledge management space. Kearney made the case that the biggest risk facing pharma content today isn’t the content you are creating now, but the content you created years ago and haven’t revisited.
In the fourth episode of Pharma Decrypted, host Sabine Louët, founder of SciencePOD, was joined by Cristina Finazzi, a customer experience director at Novartis with two decades of experience in medical congress strategy. Fresh from a season that included four major events in two weeks, Finazzi made a direct case for why in-person congresses remain irreplaceable, and why the industry’s enthusiasm for AI and digital content risks obscuring what actually changes clinical practice.
In the third episode of Pharma Decrypted, host Sabine Louët, founder of SciencePOD, was joined by Laura Kennedy, a marketing excellence and brand lead with decades of experience across the pharmaceutical industry. Kennedy, who is co-author of the forthcoming book We Don’t Sell Soap, made the case for why pharma teams need to return to marketing fundamentals and build a brand narrative before they think about execution.
The Content Crisis, the Trust Shift and the Case for Co-Creation. The key takeaways from Reuters Pharma Europe 2026 and Pharma meets AI (UBIQ Events)
A discussion with Sabine Louët and Madelene Borgvall on what to prioritise when creating multichannel campaigns
Interview with Sarah Clark-Pfister, Head of Medical Excellence and Strategic Scientific Communications, Rare Disease at Novo Nordisk
Interview with Jean Philippe Plançon, Chairman of the Board and President, European Patients Organization for Dysimmune & Inflammatory Neuropathies (EPODIN)
Interview with Itziar Canamasas, Global Head of Oncology, Boehringer Ingelheim